CY1107845T1 - Γενετικα εμβολια με ανοσοενισχυτικο - Google Patents

Γενετικα εμβολια με ανοσοενισχυτικο

Info

Publication number
CY1107845T1
CY1107845T1 CY20081100004T CY081100004T CY1107845T1 CY 1107845 T1 CY1107845 T1 CY 1107845T1 CY 20081100004 T CY20081100004 T CY 20081100004T CY 081100004 T CY081100004 T CY 081100004T CY 1107845 T1 CY1107845 T1 CY 1107845T1
Authority
CY
Cyprus
Prior art keywords
immunosuppressants
genetic immunizations
immunizations
genetic
inducing
Prior art date
Application number
CY20081100004T
Other languages
Greek (el)
English (en)
Inventor
Joel R Haynes
Georg Widera
James T Fuller
Timothy Shipley
Deborah Fuller
Mary Wu
Original Assignee
Powderject Vaccines, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines, Inc. filed Critical Powderject Vaccines, Inc.
Publication of CY1107845T1 publication Critical patent/CY1107845T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
CY20081100004T 1999-11-03 2008-01-02 Γενετικα εμβολια με ανοσοενισχυτικο CY1107845T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1999/025854 WO2001032208A1 (en) 1999-11-03 1999-11-03 Adjuvanted genetic vaccines
EP99956885A EP1227840B1 (en) 1999-11-03 1999-11-03 Adjuvanted genetic vaccines

Publications (1)

Publication Number Publication Date
CY1107845T1 true CY1107845T1 (el) 2013-06-19

Family

ID=22273970

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100004T CY1107845T1 (el) 1999-11-03 2008-01-02 Γενετικα εμβολια με ανοσοενισχυτικο

Country Status (14)

Country Link
EP (1) EP1227840B1 (https=)
JP (1) JP2003516936A (https=)
CN (1) CN100333794C (https=)
AT (1) ATE374622T1 (https=)
AU (1) AU780448C (https=)
CA (1) CA2389686A1 (https=)
CY (1) CY1107845T1 (https=)
DE (1) DE69937258T2 (https=)
DK (1) DK1227840T3 (https=)
ES (2) ES2340617T3 (https=)
IL (2) IL149415A0 (https=)
NZ (1) NZ518766A (https=)
PT (2) PT1913957E (https=)
WO (1) WO2001032208A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1227840T1 (sl) * 1999-11-03 2008-02-29 Powderject Vaccines Inc Genetske vakcine z adjuvansom
JP2004535799A (ja) * 2001-05-18 2004-12-02 パウダージェクト ワクチンズ，インコーポレーテッド ワクチン組成物
US7566478B2 (en) 2001-07-25 2009-07-28 Nantero, Inc. Methods of making carbon nanotube films, layers, fabrics, ribbons, elements and articles
CN103372217B (zh) * 2012-04-28 2014-12-10 中国科学院深圳先进技术研究院 聚合物纳米载体制剂及其制备方法和应用
WO2014145906A2 (en) * 2013-03-15 2014-09-18 Phd Preventative Health Care And Diagnostics, Inc. A prefilled medication device, method of making and using the same
US11771761B2 (en) 2019-06-12 2023-10-03 Wisconsin Alumni Research Foundation Adjuvant for animal and human vaccines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE303160T1 (de) * 1993-08-11 2005-09-15 Jenner Technologies Impfstoff gegen prostatakrebs
CA2158733C (en) * 1994-01-21 2007-01-16 Dennis E. Mccabe Gas driven gene delivery instrument
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
DE69738597T2 (de) * 1996-02-09 2008-07-24 Glaxosmithkline Biologicals S.A. Vakzine gegen das varicella zostervirus produkt von gen 63
EP1017283B1 (en) * 1997-02-14 2004-12-15 Merck & Co., Inc. Polynucleotide vaccine formulations
WO1998046263A1 (en) * 1997-04-14 1998-10-22 University Of Massachusetts Medical Center Saponin adjuvants in combination with dna vaccination
NZ504894A (en) * 1997-12-02 2002-12-20 Powderject Vaccines Inc Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique
GB9818627D0 (en) * 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
CU22740A1 (es) * 1998-09-07 2002-02-28 Ct Ingenieria Genetica Biotech Formulación de ácidos nucleicos y acemanano

Also Published As

Publication number Publication date
CN1426309A (zh) 2003-06-25
PT1227840E (pt) 2008-01-09
PT1913957E (pt) 2010-05-05
DE69937258D1 (de) 2007-11-15
ATE374622T1 (de) 2007-10-15
CA2389686A1 (en) 2001-05-10
CN100333794C (zh) 2007-08-29
AU1339900A (en) 2001-05-14
EP1227840B1 (en) 2007-10-03
ES2340617T3 (es) 2010-06-07
AU780448C (en) 2006-02-23
IL149415A (en) 2008-11-03
DK1227840T3 (da) 2008-02-04
ES2294864T3 (es) 2008-04-01
DE69937258T2 (de) 2008-07-03
JP2003516936A (ja) 2003-05-20
AU780448B2 (en) 2005-03-24
EP1227840A1 (en) 2002-08-07
IL149415A0 (en) 2002-11-10
WO2001032208A1 (en) 2001-05-10
NZ518766A (en) 2005-07-29

Similar Documents

Publication Publication Date Title
DK1487485T3 (da) Imidazoquinolinadjuvanser til DNA-vacciner
Kallen et al. A novel, disruptive vaccination technology: self-adjuvanted RNActive® vaccines
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
DE69929444D1 (de) Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
CY1107845T1 (el) Γενετικα εμβολια με ανοσοενισχυτικο
NO20051469L (no) Immunstimulerende nukleinsyrer.
DK1459766T3 (da) Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
DE60139563D1 (de) Nukleinsäuren und proteine von gruppen a und b-streptokokken
BR9906927A (pt) Proteìnas de neisseria meningitidis
CY1113185T1 (el) Μεθοδοι συνενωσης αποδεκτη πεπτιδιου
BR0113982A (pt) Uso de imidazoquinolinaminas como adjuvantes em vacinação de dna
DE69739515D1 (de) Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung.
EP2371387A3 (en) HIV consensus sequence antigens and their use in vaccina
DE60037900D1 (de) Chlamydia antigene und entsprechende dna-fragmente und ihre verwendungen
WO2002032943A3 (en) Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
WO2004098526A3 (en) Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
ATE370745T1 (de) Verbesserte polysaccharid- und glykokonjugat- vakzine
WO1999053960A3 (en) Enhancing immune responses to genetic immunization by using a chemokine
CY1107784T1 (el) Πρωτεϊνη συντηξης g του ihnv για διεγερση του ανοσοποιητικου συστηματος
DE69922212D1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
ATE460945T1 (de) Genetische adjuvanz-impfstoffe
CO5650177A2 (es) Constructos geneticos y composiciones que comprenden rre y cte y usos de estos
BR9910153A (pt) ácido nucléico e polipeptìdeos de cd80 de felino, cd80 de felino, cd28 de felino e ctla-4 de felino
ATE414905T1 (de) Diabetesmodell
SG166673A1 (en) Immunostimulatory nucleic acids